MedTrace Logo

Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

NCT04643418 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-11-03

No results posted yet for this study

Summary

This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.

Conditions

  • Solid Tumor, Unspecified, Adult

Interventions

DRUG

MPB-1734

Administered once daily in a 21-day cycle

Sponsors & Collaborators

  • MegaPro Biomedical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Muh-Hwa Yang, MD · Taipei Veterans General Hospital, Taiwan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-08
Primary Completion
2025-03-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04643418 on ClinicalTrials.gov